|
| Thursday, 6 September 2012, 19:00 HKT/SGT | |
| |  | |
Source: A*STAR | |
|
|
|
SINGAPORE, Sept 6, 2012 - (ACN Newswire) - Scientists from A*STAR's Singapore Institute for Clinical Sciences (SICS), together with clinical collaborators from London(1), discovered for the first time that children and young patients with chronic Hepatitis B Virus infection (HBV carriers) do have a protective immune response, contrary to current belief, and hence can be more suitable treatment candidates than previously considered.
This discovery by the team of scientists led by Professor Antonio Bertoletti, programme director and research director of the infection and immunity programme at SICS, could lead to a paradigm shift in the current treatment of patients with chronic HBV. The findings were published in Gastroenterology on 1st September.
Current guidelines from international liver associations recommend delaying therapy until HBV carriers show clear signs of active liver disease, which generally appear after the age of 30(2). This is based on two assumptions. One, young patients are unable to react to treatment because they are immune-tolerant to the virus. This means that there is no protective immune response(3) in their body to help them get rid of the virus, and therefore, they will not run the risk of liver damage or inflammation. Two, HBV infection is largely harmless in HBV carriers until active liver disease is apparent.
However, Professor Bertoletti and his team showed that young patients are not immune tolerant as they posses HBV-specific T cells with the ability to producedistinct antiviral cytokines(4) that help the body fight against HBV. They also showed that the longer a patient is left untreated, the less effective their immune system becomes against HBV and the less able the patient will be able to clear the virus from their body even when they receive treatment.
The scientists demonstrated that the presence of HBV in the body over a long period of time is harmful to the patient due to repeated activation of T-cells which induces a progressive state of T-cell exhaustion, a state of immune system dysfunction that prevents optimal control of the infection and clearance of the virus from the body. Thus, young patients produce an immune response against HBV which is less compromised than that in older patients.
Professor Bertoletti said, "Young patients infected with HBV are most at risk of developing chronic HBV(5) but current guidelines mean that they are also the least likely to be treated. However, our findings suggest that it might be better to start treatment early as young people with their stronger immune system, respond better to treatment and are more able to clear the virus."
Prof Judith Swain, Executive Director of SICS, said, "These findings may change the way treatment is applied to patients with HBV in hospitals in Singapore and throughout the world. This is a fine example of how clinicians, physician scientists, and scientists work together to improve healthcare for the public."
Background on HBV
HBV infection affects 400 million people worldwide, 75% of whom reside in Asia. In Singapore, one in every 35 adult is a Hepatitis B carrier.(6) Hepatitis B is the most common infection of the liver that is spread by direct contact with the blood or body fluids of an infected person. Not all HBV carriers display symptoms but lifelong infection carries the risk of serious health complications including cirrhosis, hepatocellular carcinoma, and liver failure.
The research findings described in this news release can be found in the volume 143 N 3 issue of Gastroenterology under the title "Preserved T-Cell Function in Children and Young Adults With Immune-Tolerant Chronic Hepatitis B", by Patrick Kennedy, Elena Sandalova, Juandy Jo, Upkar Gill, Ines Ushiro-Lumb, Anthony Tan, Sandhia Naik, Graham Foster, and Antonoio Bertoletti. The paper can be accessed at http://www.gastrojournal.org/article/S0016-5085(12)00840-2/abstract.
(1) Institute of Cell and Molecular Science, Barts and The London School of Medicine & Dentistry, London, England
(2) http://gut.bmj.com/content/early/2011/12/06/gutjnl-2011-300937.extract
(3) Hepatitis B causes liver disease when the body's immune system is unable to clear the virus and causes damage via inflammation instead. When the human body is infected with HBV, the immune response attempts to get rid of the virus. While this is a protective response, the same immune response can actually harm the body by causing damage to the liver via inflammation if it is unable to clear the body of the virus successfully.
(4) Cytokines are proteins that are produced by cells. Cytokines interact with cells of the immune system in order to regulate the body's response to disease and infection. Cytokines also mediate normal cellular processes in the body.
(5) The risk of developing a chronic hepatitis B infection is directly related to the age at which one becomes infected with the virus. About 90% of infants infected at birth and up to 50% of young children infected between the ages of one and five years will develop a chronic hepatitis B infection.
(6) http://www.hpb.gov.sg/HOPPortal/dandc-article/536#dvHEPB_Pg1_menu
About the Singapore Institute for Clinical Sciences (SICS)
Established in 2007, the Singapore Institute for Clinical Sciences (SICS) is a research institute within the Agency for Science, Technology and Research (A*STAR), and its mission is to develop disease-oriented clinical and translational research programmes in key disease areas.
SICS is distinguished by its focus on clinical sciences and the use of innovative approaches and technologies that enable the efficient and effective study of human health and diseases. The clinical scientists in SICS conduct the full spectrum of "bench to bedside" research activities in metabolic diseases (including diabetes, obesity and insulin resistance), pathways to normal growth and development (including cognitive and behavioural development), nutritional sciences as well as in certain viral infectious diseases such as chronic viral diseases.
The institute aims to attract, train and nurture clinician-scientists and to develop joint programs with universities, academic medical centres, government hospitals and research institutes. For more information on SICS, please visit: www.sics.a-star.edu.sg
Contact:
Ong Siok Ming (Ms)
Senior Officer, Corporate Communications
Agency for Science, Technology and Research
Tel: +65 6826 6254
Email: ong_siok_ming@a-star.edu.sg
Topic: Research and development
Source: A*STAR
Sectors: Science & Research
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
| A*STAR |
| Dec 6, 2022 14:00 HKT/SGT |
|
Global pharma giants partner Singapore researchers to boost innovation in biologics and vaccines manufacturing |
| June 2, 2022 21:00 HKT/SGT |
|
Boehringer Ingelheim Enters Global Licensing Agreement to Develop and Commercialize Innovative Antibodies from A*STAR for Targeted Cancer Therapies |
| June 2, 2022 21:00 HKT/SGT |
|
Boehringer Ingelheim Enters Global Licensing Agreement to Develop and Commercialize Innovative Antibodies from A*STAR for Targeted Cancer Therapies |
| Sept 30, 2021 16:00 HKT/SGT |
|
A*STAR and Local SME Work with Vaccination Centres to Deploy AVID System for Filling Syringes |
| July 31, 2020 08:00 HKT/SGT |
|
Singapore Cancer Drug ETC-159 Advances Further in Clinical Trials |
| July 24, 2020 17:00 HKT/SGT |
|
MP Biomedicals and A*STAR Co-Develop Rapid Antibody Test Kit for SARS-CoV-2 |
| Oct 22, 2019 04:00 HKT/SGT |
|
Fujitsu, SMU and A*STAR Launch Digital Platform Experimentation Project using Quantum-Inspired Computing and Deep Learning Technology |
| June 28, 2019 08:00 HKT/SGT |
|
Singapore's Drug Development Efforts Given Additional Momentum with National Platforms |
| Apr 5, 2019 18:00 HKT/SGT |
|
Passing of Dr Sydney Brenner, Nobel Laureate, Renowned Pioneer in Molecular Biology, A*Star Senior Fellow |
| Jan 21, 2019 13:00 HKT/SGT |
|
Branched-Chain Amino Acids Found to Regulate the Development and Progression of Cancer |
| More news >> |
 |
|
|
|
